FY2027 EPS Estimate for Kura Oncology Decreased by Analyst

Kura Oncology, Inc. (NASDAQ:KURA) – Brookline Capital Acquisition lowered their FY2027 earnings per share (EPS) estimates for shares of Kura Oncology in a research report issued on Thursday, March 5th. Brookline Capital Acquisition analyst L. Cann now anticipates that the company will post earnings per share of $0.31 for the year, down from their previous forecast of $0.32. The consensus estimate for Kura Oncology’s current full-year earnings is ($2.44) per share. Brookline Capital Acquisition also issued estimates for Kura Oncology’s FY2028 earnings at $3.59 EPS, FY2029 earnings at $11.61 EPS and FY2030 earnings at $26.58 EPS.

Other equities research analysts have also issued reports about the stock. HC Wainwright reiterated a “buy” rating and issued a $40.00 price objective on shares of Kura Oncology in a research report on Tuesday, January 13th. Wedbush dropped their target price on shares of Kura Oncology from $38.00 to $36.00 and set an “outperform” rating for the company in a report on Friday. Barclays restated an “overweight” rating and set a $28.00 target price (up from $11.00) on shares of Kura Oncology in a research report on Monday, November 24th. Citigroup reiterated a “market outperform” rating on shares of Kura Oncology in a research report on Friday, December 5th. Finally, Wall Street Zen cut shares of Kura Oncology from a “hold” rating to a “sell” rating in a research note on Monday, March 2nd. Nine equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Kura Oncology has an average rating of “Moderate Buy” and a consensus target price of $27.71.

Kura Oncology Stock Up 4.8%

Kura Oncology stock opened at $9.39 on Monday. Kura Oncology has a fifty-two week low of $5.41 and a fifty-two week high of $12.49. The firm has a market capitalization of $829.42 million, a price-to-earnings ratio of -2.95 and a beta of 0.22. The stock’s fifty day moving average is $8.73 and its two-hundred day moving average is $9.44. The company has a debt-to-equity ratio of 0.06, a quick ratio of 6.05 and a current ratio of 6.06.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings data on Thursday, March 5th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by ($0.20). The firm had revenue of $17.34 million for the quarter, compared to analyst estimates of $34.71 million. Kura Oncology had a negative return on equity of 102.59% and a negative net margin of 412.95%.

Hedge Funds Weigh In On Kura Oncology

A number of institutional investors have recently modified their holdings of the company. Virtu Financial LLC acquired a new position in shares of Kura Oncology in the fourth quarter valued at approximately $349,000. Invesco Ltd. boosted its position in Kura Oncology by 14.6% during the fourth quarter. Invesco Ltd. now owns 209,370 shares of the company’s stock worth $2,175,000 after acquiring an additional 26,683 shares during the last quarter. Mercer Global Advisors Inc. ADV boosted its position in Kura Oncology by 52.3% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 50,080 shares of the company’s stock worth $520,000 after acquiring an additional 17,197 shares during the last quarter. Voloridge Investment Management LLC purchased a new stake in Kura Oncology in the 4th quarter worth approximately $2,505,000. Finally, Virtus Investment Advisers LLC grew its stake in Kura Oncology by 291.4% in the 4th quarter. Virtus Investment Advisers LLC now owns 66,870 shares of the company’s stock worth $695,000 after acquiring an additional 49,785 shares during the period.

Insider Buying and Selling at Kura Oncology

In related news, insider Mollie Leoni sold 8,180 shares of Kura Oncology stock in a transaction dated Tuesday, January 27th. The stock was sold at an average price of $8.46, for a total transaction of $69,202.80. Following the completion of the sale, the insider owned 267,274 shares in the company, valued at approximately $2,261,138.04. This trade represents a 2.97% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Teresa Brophy Bair sold 11,208 shares of the business’s stock in a transaction dated Tuesday, January 27th. The shares were sold at an average price of $8.46, for a total transaction of $94,819.68. Following the completion of the transaction, the insider directly owned 226,931 shares of the company’s stock, valued at $1,919,836.26. The trade was a 4.71% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 59,794 shares of company stock valued at $537,176. 6.40% of the stock is owned by company insiders.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.